Vivo Capital LLC Lowers Holdings in Biopharmx Corp (NYSEAMERICAN:BPMX)
Vivo Capital LLC trimmed its holdings in Biopharmx Corp (NYSEAMERICAN:BPMX) by 98.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 317,270 shares of the biotechnology company’s stock after selling 15,811,245 shares during the quarter. Vivo Capital LLC owned 3.03% of Biopharmx worth $189,000 at the end of the most recent reporting period.
Separately, Deutsche Bank AG boosted its stake in shares of Biopharmx by 1,256.5% during the 4th quarter. Deutsche Bank AG now owns 549,973 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 509,430 shares in the last quarter.
In other news, major shareholder Vivo Capital Viii, Llc sold 327,870 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $1.02, for a total transaction of $334,427.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Biopharmx (NYSEAMERICAN:BPMX) last announced its quarterly earnings results on Monday, September 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.12.
Separately, Maxim Group set a $1.00 target price on shares of Biopharmx and gave the stock a “buy” rating in a research note on Monday.
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
Recommended Story: Benefits of owning preferred stock
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.